Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party.
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party.
G. Schuurhuis,M. Heuser,21 Authors,G. Ossenkoppele
2018 · DOI: 10.1182/blood-2017-09-801498
Blood · 927 Citations
TLDR
The objective of this work was to identify key clinical and scientific issues in the measurement and application of MRD in AML, to achieve consensus on these issues, and to provide guidelines for the current and future use of MRd in clinical practice.